BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23334230)

  • 1. New developments in biomarkers for melanoma.
    Griewank KG; Ugurel S; Schadendorf D; Paschen A
    Curr Opin Oncol; 2013 Mar; 25(2):145-51. PubMed ID: 23334230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.
    Neagu M; Constantin C; Tanase C
    Expert Rev Mol Diagn; 2010 Oct; 10(7):897-919. PubMed ID: 20964610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
    Bougnoux AC; Solassol J
    Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
    Martinez SR; Hoon DS
    J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immuno-diagnosis of malignant melanoma].
    Szekeres G; Battyáni Z
    Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response.
    Quandt D; Fiedler E; Boettcher D; Marsch WCh; Seliger B
    Clin Cancer Res; 2011 May; 17(10):3100-11. PubMed ID: 21378130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers in melanoma.
    Kashani-Sabet M
    Br J Dermatol; 2014 Jan; 170(1):31-5. PubMed ID: 23815339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
    Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
    Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics of melanoma: implications for immune-based therapies.
    Fratta E; Sigalotti L; Covre A; Parisi G; Coral S; Maio M
    Immunotherapy; 2013 Oct; 5(10):1103-16. PubMed ID: 24088079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Biomarkers in Cutaneous Melanoma.
    Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
    Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marker utility for combination therapy.
    Simeone E; Grimaldi AM; Ascierto PA
    Methods Mol Biol; 2014; 1102():97-115. PubMed ID: 24258976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-associated antigens as messenger RNA detection markers for melanoma.
    Sarantou T; Chi DD; Garrison DA; Conrad AJ; Schmid P; Morton DL; Hoon DS
    Cancer Res; 1997 Apr; 57(7):1371-6. PubMed ID: 9102226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
    Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
    Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and genetic mechanisms in melanoma.
    Gruber F; Kastelan M; Brajac I; Saftić M; Peharda V; Cabrijan L; Stanić Zgombić Z; Simonić E
    Coll Antropol; 2008 Oct; 32 Suppl 2():147-52. PubMed ID: 19138018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
    Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
    Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers of circulating melanoma cells.
    Medic S; Pearce RL; Heenan PJ; Ziman M
    Pigment Cell Res; 2007 Apr; 20(2):80-91. PubMed ID: 17371435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic markers of prognosis in melanoma.
    Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
    Methods Mol Biol; 2014; 1102():481-99. PubMed ID: 24258994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.
    Ladányi A
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):490-500. PubMed ID: 25818762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diagnostics in melanoma.
    Carlson JA; Ross JS; Slominski A; Linette G; Mysliborski J; Hill J; Mihm M
    J Am Acad Dermatol; 2005 May; 52(5):743-75; quiz 775-8. PubMed ID: 15858465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
    Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
    J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.